Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
The vaccines are currently only authorised for emergency use in the country
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Subscribe To Our Newsletter & Stay Updated
